Vasculitis syndromes: Tocilizumab — a new frontier for GCA therapy
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Rheumatology"
DOI: 10.1038/nrrheum.2017.150
Abstract: An unmet need exists for effective glucocorticoid-sparing agents for the treatment of giant cell arteritis (GCA). Tocilizumab, the first intervention to demonstrate substantial therapeutic benefits for patients with newly diagnosed or relapsing GCA, is changing… read more here.
Keywords: frontier gca; syndromes tocilizumab; vasculitis syndromes; tocilizumab new ... See more keywords